Otulfi (Ustekinumab)

Ustekinumab binds to the p40 subunit shared by interleukin‑12 and interleukin‑23, preventing these cytokines from activating their receptors on immune cells. This blocks the downstream inflammatory cascade that drives the skin and gut lesions seen in psoriasis and inflammatory bowel disease.

The dosing schedule for ustekinumab is individualized by the prescribing clinician based on the specific indication, patient weight, and prior treatment response. The prescriber determines the initial dose, maintenance interval and any necessary adjustments.

Safety data for ustekinumab in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a specialist obstetrician and the treating physician.

To request Otulfi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with TNF‑α inhibitors, ustekinumab targets a different cytokine pathway (IL‑12/IL‑23) and is administered less frequently, which may improve convenience. Efficacy and safety profiles differ, so the choice depends on disease characteristics, prior therapy response and patient preference.

Otulfi should be stored in a refrigerator at 2‑8 °C, protected from light and never frozen. Once removed from refrigeration, the product may be kept at room temperature for a limited period as specified in the labeling, but should be returned to the fridge if not used promptly.

Otulfi is supplied as a pre‑filled syringe for subcutaneous injection. A healthcare professional administers the dose under aseptic technique, typically in the thigh, abdomen or upper arm, following the dosing schedule prescribed by the treating physician.

Serious risks include severe infections such as tuberculosis, opportunistic fungal infections, and rare malignancies. Patients should be monitored for signs of infection, undergo regular skin examinations and report any new or worsening symptoms promptly.

Otulfi is contraindicated in individuals with known hypersensitivity to ustekinumab or any excipients, and should be used with caution in patients with active infections, uncontrolled heart disease, or a history of malignancy. A thorough medical assessment is required before initiating therapy.